Posted from: Monday, December 28, 2015 - 10:50 AM - Present

Fluad Approved for Flu Vaccination for Older Adults

November 24, 2015 – The U.S. Food and Drug Administration (FDA) approved Fluad, an inactivated trivalent influenza virus vaccine.  Fluad is manufactured by Seqirus. Trivalent vaccines protect against two strains of type A influenza virus and one strain of type B.  Fluad is indicated for individuals age 65 years and older.  This population typically has the highest numbers of flu-related complications, hospitalizations and deaths. Fluad is the first vaccine approved in the U.S. that includes an adjuvant to boost the body’s immune response. Fluad will be supplied in single-dose, pre-filled syringes with 0.5mL of vaccine to be administered as one intramuscular (IM) injection into the upper arm.  A launch date and pricing for Fluad have not yet been released. Sanofi-Pasteur’s Fluzone High-Dose (influenza vaccine) is the only other flu vaccine specifically designed for immunizing individuals who are 65 years old or older. 

 

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability. All trademarks are the property of their respective owners.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Thursday, August 17, 2017 - 12:25 AM.